Original Publication Date: 1 July, 2016
Publication / Source: Future Oncology
Authors: Pilar de la Puente & Abdel Kareem Azab
Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow (BM), which remains incurable because most patients relapse or become refractory to the treatments . The American Cancer Society’s estimates for MM in the USA for 2016 about 30,000 new cases will be diagnosed and about 12,500 deaths will occur. Newly diagnosed MM patients with standard-risk disease are associated with a median overall survival of about 4 years, whereas high-risk disease MM patients are associated with a median overall survival of about 2 years .